Business
Blue Water Biotech Announces It Has Regained Compliance with Nasdaq Listing Rule 5250(c)(1)
CINCINNATI, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (Nasdaq: BWV) ("BWB" or the “Company”) today announced that it has received a letter
About this update from Onconetix, Inc.
CINCINNATI , Nov. 01, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (Nasdaq: BWV) ("BWB" or the “Company”) today announced that it has received a letter from the Nasdaq Stock Market, LLC ("Nasdaq") stating that the Company has regained compliance with the Nasdaq Stock Market , LLC Listing Rule 5250(c)(1) (the "Rule"). The Rule requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (SEC). On October 20, 2023 , BWB filed its Form 10-Q for the period ended June 30, 2023 , and thus is now current on its SEC financial reporting obligations. About Blue Water Biotech, Inc. Blue Water Biotech, Inc. is a commercial stage biotechnology company focused on the research, development, and commercialization of innovative solutions for oncology. The Company currently has Entadfi®, an oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology. Investor and Media Contact Information: Russo Partners, LLC Nic Johnson and Harrison Seidner , PhDTelephone: (212) 845-4242 Email: [email protected] Source: Blue Water Biotech, Inc.